Short Sellers Back Off Major Biotechs
As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears have to say about this rally.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 178
Short Sellers Run for Cover From Major Pharma
The January 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly down.
What to Expect From Major Health Care Stocks Reporting This Week
The health care sector has some of its biggest players reporting later this week, with one pharma giant’s report already out of the way.
Ocular Therapeutics Sinks Following Secondary Offering
Ocular Therapeutix, Inc. (NASDAQ: OCUL) saw its shares take a dive on Tuesday after the company announced the pricing of its secondary offering. The company is pricing its 3.57 million shares at $7 per…
4 Speculative Biotech and Biohealth Analyst Upgrades
It seems that analysts are taking the forefront and making calls on where the biopharma industry is going ahead of action by the Trump administration.
Despite Pharma Risks, Jefferies Likes 4 Top Contract Research Stocks
The contract research organizations, or CROs, may offer a lot of value as companies look to bring in help from the outside in drug studies and development.
Johnson & Johnson Revenues, 2017 Outlook Weigh on Shares
Johnson & Johnson offer disappointing 2017 outlook and announce that it is reviewing options, including possible sales, of its diabetes businesses.
Why This Seizure Drug Matters So Much for Marinus Pharma
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) saw its shares climb on Monday after the company reported positive preliminary results from its mid-stage trial. Specifically the data came from Mirna’s Phase 2 study evaluating ganazolone as…
Why Credit Suisse Sees Incyte Rising Over 15%
Credit Suisse sees future earnings growth from Incyte’s pipeline, with epacadostat’s potential as a best-in-class immunotherapy combination agent making the stock an attractive takeout target.
Why Credit Suisse Sees 25% Upside at BioMarin
BioMarin Pharmaceutical may have missed out on the Trump rally, but it might not be too late to catch a ride on the wave, at least according to one analyst.
Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017
A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks to buy that have a large enough market cap to provide some safety.
Thursday’s Top Biopharma Movers
Not that many biotech and pharma companies were on the move Thursday, just one day before the inauguration. However, a few of the smaller caps made splash.
Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential
A recent research report from the biotech team at Baird offers their top picks for 2017. While hardly pounding the table, they are cautiously optimistic on the industry.
How Erectile Dysfunction in Mexico Just Made One Micro-Cap Stock More Than Double
The biotechs and emerging pharma have been under pressure from politicians attacking drug prices. That doesn't mean that there are not some big winners out there.
Wednesday’s Top Biopharma Winners
Trump said last week that companies in the health care sector are “getting away with murder,” and that something had to change. The sector has pulled back slightly since then, but there are still…